Compare Dyne Therapeutics Inc. Common Stock (DYN) vs Hilton Hotels Corporation Common Stock (HLT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dyne Therapeutics Inc. Common Stock vs Hilton Hotels Corporation Common Stock — how do they compare? Dyne Therapeutics Inc. Common Stock trades at $15.09 (market cap $2.86B), while Hilton Hotels Corporation Common Stock trades at $329.1 (market cap $74.18B). The key difference: Hilton Hotels Corporation Common Stock is far larger — about 25.9× Dyne Therapeutics Inc. Common Stock's market cap, and Hilton Hotels Corporation Common Stock pays a 0.18% dividend while Dyne Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Dyne Therapeutics Inc. Common Stock for 0 Days and Hilton Hotels Corporation Common Stock for 139 Days on average.
| DYN | HLT | |
|---|---|---|
Market Cap | $2.86B | $74.18B |
Volume | 3,341,579 | 1,295,545 |
Sector | Health | Consumer Cyclical |
52-Week High | $26.78 | $350.22 |
52-Week Low | $14.60 | $256.96 |
Typical Hold Time | 0 Days | 139 Days |
Enterprise Value | $2.18B | $87.19B |
Dividend Yield | — | 0.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dyne Therapeutics (DYN) trades at $15.30, down 4.14% on the day, reflecting recent volatility amid mixed clinical trial news. The stock is in a neutral technical position with immediate support at $15 and resistance at $16. Fundamentally, the company is a clinical-stage biotech with no revenue, reporting a net loss of $446.21M in 2025, but maintains strong analyst support with an 85.7% buy rating and a $35.20 consensus price target. Recent news highlights progress in Phase 1/2 trials for neuromuscular diseases and a $375M public offering in July 2026 to fund development.
The investment case hinges on clinical success, offering significant upside to the price target, but carries high risk due to pre-revenue status, dependence on trial outcomes, and negative cash flow from operations. Investor sentiment is cautiously optimistic, buoyed by analyst confidence, though volatility from sector-specific news remains a near-term challenge.
Hilton Worldwide (HLT) trades at $328.12, up 0.18% on the day, with strong technical momentum as the stock approaches resistance near $330. The company demonstrates solid fundamental performance with revenue growth from $12.04B in 2025 to projected $12.5B in 2026, consistently beating earnings expectations in recent quarters. Analyst sentiment remains bullish with 57% buy ratings and a $350 consensus price target, supported by institutional accumulation and positive travel industry trends.
HLT presents a compelling investment case with strong earnings momentum and global portfolio expansion, though elevated valuation metrics (P/E 48.4) and rising debt levels warrant caution. The stock's proximity to technical resistance and overbought RSI readings suggest potential near-term consolidation before further upside toward analyst targets. Key risks include macroeconomic sensitivity and competitive pressures in the hospitality sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Dyne Therapeutics Inc. Common Stock
Dyne Therapeutics, Inc. is a clinical-stage biotechnology company developing therapeutics for genetically driven neuromuscular diseases, including Duchenne muscular dystrophy and myotonic dystrophy type 1, with additional preclinical programs for facioscapulohumeral muscular dystrophy and Pompe disease.
Read more on DYN →About Hilton Hotels Corporation Common Stock
Hilton Worldwide Holdings operates 1,074,791 rooms across its 18 brands addressing the midscale through luxury segments as of Dec. 31, 2021. Hampton and Hilton are the two largest brands by total room count at 28% and 21%, respectively, as of Dec. 31, 2021. Recent brands launched over the last few years include Home2, Curio, Canopy, Tru, and Tempo. Managed and franchised represent the vast majority of adjusted EBITDA, predominantly from the Americas regions.
Read more on HLT →
